Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1865464 | 1.00 | NPY5R (0.58) | NPY5RGAAOPRD1OPRM1OPRK1 | |
| SCHEMBL1867043 | 1.00 | NPY5R (0.58) | NPY5RGAAOPRD1OPRM1OPRK1 | |
| SCHEMBL1861747 | 0.88 | NPY5R (0.60) | NPY5RGAAOPRD1OPRM1OPRK1 | |
| SCHEMBL2645267 | 0.88 | NPY5R (0.60) | NPY5RGAAOPRD1OPRM1OPRK1 | |
| SCHEMBL1861749 | 0.88 | NPY5R (0.60) | NPY5RGAAOPRD1OPRM1OPRK1 | |
| SCHEMBL14192005 | 0.87 | NPY5R (0.65) | NPY5RGAAOPRD1OPRM1OPRK1 | |
| SCHEMBL2668153 | 0.86 | NPY5R (0.53) | NPY5RGAAOPRD1OPRM1OPRK1 | |
| SCHEMBL1857950 | 0.85 | NPY5R (0.52) | NPY5RGAAOPRD1OPRM1OPRK1 | |
| SCHEMBL1857949 | 0.85 | NPY5R (0.52) | NPY5RGAAOPRD1OPRM1OPRK1 | |
| SCHEMBL2647126 | 0.84 | NPY5R (0.55) | NPY5RGAAOPRK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935699-B2 | Pyrazole glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2011-05-03 | — | — | US | disclosed |
| EP-2261216-A2 | Pyrazoles as glucokinase activators | F. Hoffmann-La Roche AG (CH) | 2010-12-15 | — | — | EP | disclosed |
| US-20080021032-A1 | Pyrazole glucokinase activators | BERTHEL STEVEN JOSEPH | 2008-01-24 | — | — | US | disclosed |
| US-20070203207-A1 | Heteroaromatic glucokinase activators | BIZZARRO FRED T | 2007-08-30 | — | — | US | disclosed |
| EP-1572670-B1 | 5-SUBSTITUTED-PYRAZINE OR -PYRIDINE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2007-08-22 | — | — | EP | disclosed |
| US-7259166-B2 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2007-08-21 | — | — | US | disclosed |
| US-7223868-B2 | Such as 2-(3-chloro-phenyl)-3-cyclopentyl-N-thiazol-2-yl-propionamide which increases insulin secretion in treatment of type II diabetes | HOFFMANN-LA ROCHE INC. (US) | 2007-05-29 | — | — | US | disclosed |
| EP-1501815-B1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2006-11-22 | — | — | EP | disclosed |
| US-7132425-B2 | 5-substituted-six-membered heteroaromatic glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2006-11-07 | — | — | US | disclosed |
| US-7105671-B2 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2006-09-12 | — | — | US | disclosed |
| US-20060178429-A1 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | CORBETT WENDY L | 2006-08-10 | — | — | US | disclosed |
| US-20050261503-A1 | Heteroaromatic glucokinase activators | BIZZARO FRED T | 2005-11-24 | — | — | US | disclosed |
| US-6951945-B2 | Heteroaromatic glucokinase activators | HOFFMAN-LA ROCHE INC. (US) | 2005-10-04 | — | — | US | disclosed |
| WO-2003095438-A9 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2004-12-23 | — | — | WO | disclosed |
| US-20040147748-A1 | 5-Substituted-six-membered heteroaromatic glucokinase activators | CHEN SHAOQING (US) | 2004-07-29 | — | — | US | disclosed |
| US-20040014968-A1 | Heteroaromatic glucokinase activators | BIZZARRO FRED THOMAS (US) | 2004-01-22 | — | — | US | disclosed |
| US-20030225283-A1 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | CORBETT WENDY LEA (US) | 2003-12-04 | — | — | US | disclosed |
| US-6610846-B1 | Increase insulin secretion; type II diabetes; 2,3-Di-substituted N-heteroaromatic propionamides with 3- a phenyl group and 2- a methyl cycloalkyl ring; 3-cyclopentyl-2-(3,4-dichlorophenyl)-N-pyridazin-3-yl-propionamide | HOFFMAN-LA ROCHE INC. | 2003-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014968-A1 | Heteroaromatic glucokinase activators | GCKR, GCK, PDXK | NPY5R 2755/4885GAA 589/4885OPRD1 3855/4885 |
| US-20060178429-A1 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | GCKR, GCK, PDXK | NPY5R 1540/4885GAA 585/4885OPRD1 2269/4885 |
| US-20040147748-A1 | 5-Substituted-six-membered heteroaromatic glucokinase activators | GCK, GCKR, GALK1 | NPY5R 1891/4885GAA 59/4885OPRD1 3752/4885 |
| US-20030225283-A1 | Substituted-cycloalkyl and oxygenated-cycloalkyl glucokinase activators | GCKR, GCK, PDXK | NPY5R 1540/4885GAA 585/4885OPRD1 2269/4885 |
| US-20070203207-A1 | Heteroaromatic glucokinase activators | GCKR, GCK, PDXK | NPY5R 2755/4885GAA 589/4885OPRD1 3855/4885 |
| US-20050261503-A1 | Heteroaromatic glucokinase activators | GCKR, GCK, PDXK | NPY5R 2755/4885GAA 589/4885OPRD1 3855/4885 |
| US-20080021032-A1 | Pyrazole glucokinase activators | GCKR, GCK, GALK1 | NPY5R 2934/4885GAA 150/4885OPRD1 4377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.